New York, Feb. 03, 2020 (GLOBE NEWSWIRE) — Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and other food allergies, announces results from a survey fielded by Allergy & Asthma Network, a nonprofit advocacy organization. This online survey polled 259 physicians and 137 patients and parents to find out their opinions regarding peanut allergy immunotherapy treatment. Prior to Friday's FDA approval of an oral immunotherapy product involving peanut powder emptied from capsules or sachets and mixed with semisolid food and then eaten, there were no FDA-approved treatments available for any food allergy.
Results from this survey confirmed that nearly nine out of ten (87%) physicians confirmed their desire to prescribe an FDA-approved immunotherapy treatment for peanut allergy. Of importance, 89% of providers would switch patients from a peanut allergy immunotherapy to a newer product like OMIT with fewer side effects. 46% percent of physician respondents preferred a product that would target the oral cavity, such as Intrommune's oral mucosal immunotherapy toothpaste, while 18% preferred powder mixed into food and eaten (oral immunotherapy/OIT).
“These survey findings are encouraging as we see peanut allergy immunotherapies progress toward FDA approval,” said Michael Nelson, CEO, Intrommune. “The FDA's approval of an oral immunotherapy for peanut allergy highlights the unmet medical needs of food-allergic individuals.”
“These survey data also clearly show that physicians are ready and willing to utilize these new treatments as they enter the market,” said Erick Berglund, PhD, Chief Scientific Officer. “As other peanut allergy immunotherapies become available, physicians will have more choices for patients and parents. Peanut INT301 is the only product under development that enables regular and convenient extended use of allergy immunotherapy by integrating naturally into a person's ordinary everyday routine of tooth brushing.”
Additional results from this survey showed that 90% of patients and parents said …
Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is not paid to share this information. Cannabis Investment Group is not paid to share this information and has no business relationship other than shareholder with any company whose stock is mentioned in this article.